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Introduction
Post Attenuation Neurological Signs (PANS) are a complication of the surgical management of Congenital Portosystemic Shunts (CPSS) reported in up to 12% of dogs. [1] [2] [3] [4] [5] [6] [7] Signs vary from mild ataxia 2, 8 to generalized seizure activity. 5, 6, 9 PANS is a well recognised complication in dogs, however, the underlying aetiology is unclear and may be linked to changes associated with hepatic encephalopathy (HE) prior to surgery. 6, 9 Dogs with CPSS often show signs of HE, a poorly understood syndrome of neurological signs caused by alterations of multiple factors including ammonia and false neurotransmitters. [10] [11] [12] In dogs with CPSS, ammonia and inflammatory mediators predict the presence of HE 13 and indicators of inflammation reduce following successful CPSS attenuation. 14 HE is commonly observed in people secondary to a variety of liver diseases, however the pathogenesis remains unclear.
HE may cause chronic alterations in the central nervous system [15] [16] [17] [18] [19] and there is direct evidence of astrocyte alterations in the brains of dogs with CPSS. 10, 21 It is hypothesised that the central nervous system becomes adapted to an abnormal metabolic environment pre-operatively and a sudden change to this favours an excitatory state. 2 Alternatively, damage to the CNS as a result of chronic portosystemic shunting, coupled with a metabolic event post attenuation could result in PANS. 6 PANS is recognised to be a separate entity to HE, 1 occurring even when the CPSS is fully attenuated at surgery. 22, 23 In one study all animals affected with PANS had normal levels of ammonia, 24 whereas HE is commonly associated with hyperammonaemia. 13 Increasing age has been associated with PANS in some studies 2,6,9 , but not others. 25, 26 There is conflicting evidence about whether dogs with extrahepatic shunts carry an increased risk of developing PANS, and the effect of the method or degree of shunt attenuation is unknown. 2, 4, 23, 25, 27 Changes in sodium affect osmolality. Central pontine myelinolysis is one of the most severe causes of post-operative neurological signs in people undergoing orthotopic liver transplantation and is associated with rapid correction of hyponatraemia. 28 In addition a reduction of osmolality is associated with increased risk of seizures in people and other animals. 19, 29 Administration of prophylactic anti-seizure medication to dogs with CPSS in the perioperative period has shown mixed results. Peri-operative levetiracetam seemed to reduce the incidence of post-operative seizures in one retrospective study, 3 whereas phenobarbitone potentially reduced the severity, but not the incidence of neurological dysfunction in another. 2 The aim of the current study was to retrospectively review the records of dogs that had undergone surgical attenuation of a single CPSS, to describe the incidence, outcome and identify risk factors for PANS and seizures. We hypothesised that age, the presence of HE pre-surgery, extrahepatic shunt morphology and alterations in osmolality postoperatively would be significantly associated with the incidence of PANS and seizures.
Additionally, we hypothesised that peri-operative administration of levetiracetam would not affect the incidence of PANS or seizures.
Materials and Methods
The records of dogs that underwent surgery for the attenuation of a single congenital portosystemic shunt at our institution between February 2000 and July 2015 were reviewed. Diagnosis of a single CPSS was confirmed at surgery with a mesenteric portovenogram in all cases. 30 The details recorded were signalment, bodyweight, duration of clinical signs related to a CPSS, (neurological, urinary and gastrointestinal), severity and duration of HE prior to surgery, response to medical treatment prior to surgery, pre-surgery serum albumin, pre and 24hr post-operative plasma ammonia, perioperative levetiracetam, shunt type (intrahepatic or extrahepatic), method of attenuation and the degree of attenuation achieved, post-operative serum osmolality at three time points, the nature, timing and outcome of any complications related to PANS and the number of days hospitalisation. Ammonia was measured using a Stasar III Spectrophotometer (Gilford Instrument Laboratories Incorporated, Ohio, USA) or a Jenway 6310 Spectrophotometer (Bibby Scientific Limited, Staffordshire, UK). Albumin was measured using a ILab 600 clinical chemistry analyser (Instrumentation Labaratory, Werfen, Warrington, UK).
Electrolytes, urea (BUN) and glucose were measured using a blood gas analyser.
Osmolality was calculated by the blood gas analyser using the following formula: HE before the commencement of medical management (Table 1 ) and immediately preoperatively ( Table 2 ) was graded. Dogs were deemed to have PANS if any neurological signs were noted after surgery and before discharge. PANS were graded as mild, moderate or severe ( Table 3 ). Dogs underwent CPSS attenuation according to a standardized surgical protocol. 25, 30 The anaesthesia protocol was at the discretion of the anaesthetist. As previously reported, the decision to partially or completely attenuate the CPSS was made on the basis of portal pressure measured via mesenteric vein catheterization and visual assessment of the pancreas and intestinal tract for signs of portal hypertension. Dogs that could tolerate a complete attenuation were treated with a complete acute suture ligation, those that could not were treated either with a partial suture ligation or a cellophane band. 30 Statistical analysis was performed using the statistical software package IBM SPSS Univariable binary logistic regression was performed using each potential predictor variable ( Tables 5 and 6 ) as an initial screening to identify possible risk factors for PANS and seizures for use in multivariable models.
Variables were selected for univariable binary logistic regression that had been previously associated with outcome or were related to the study hypothesis. 2, 3, 6, 13, 19, 31 Multivariable binary logistic regression models were then developed initially using the variables with a P ≤ 0.10 in the univariable analysis. Variables were sequentially entered into the logistic regression model and retained if P ≤ 0.05. Once the model was finalized, excluded variables were re-assessed by individually re-entering them back into the model. Two models were created, one for PANS and one for seizures.
Correlation between variables used in the multivariable analysis was assessed using a Spearman's Rank Correlation.
Results
Two hundred and fifty-three dogs with a single CPSS were included in the study. Three other cases were omitted due to incomplete medical records. Where dogs had more than one surgery only the details of the first surgery were included. One hundred and thirtyseven dogs (54.2%) were male and 116 dogs (45.8%) were female. One hundred and seventy-five dogs (69.2%) were intact and 78 dogs (30.8%) were neutered. The median age at time of surgery was 0.87 years (range 0.20-11.98). The median weight at surgery was 6.3kg (range 1.0-50.0).
The median duration of clinical signs prior to surgery was 57 days (range 5-1436). HE grade prior to medical management was 1 in 71 dogs (28.1%), 2 in 108 dogs (42.7%), 3 in 72 dogs (28.5%) and 4 in two dogs (0.8%). Two hundred and thirty-eight dogs (94.1%) were treated with medical management prior to surgery and 15 dogs (5.9%) did not receive any treatment. Of the 238 dogs that had medical management prior to surgery there was a good response in 176 dogs (73.9%), a moderate response in 49 dogs (20.6%) and a poor response in 13 (5.5%). The HE grade following medical management was grade 1 in 196 dogs (82.4%), grade 2 in 37 dogs (15.5%), grade 3 in four dogs (1.7%) and grade 4 in one dog (0.4%). The median duration of medical management prior to surgery was 23 days (range 0-730).
One hundred and ninety-six dogs (77.5%) had an extrahepatic CPSS and 57 dogs (22.5%) had an intrahepatic CPSS. One hundred and forty-eight dogs (58.5%) were able to tolerate a partial attenuation and 105 dogs (41.5%) were able to tolerate a complete attenuation. Of the 148 dogs treated with a partial attenuation 12 (8.1%) were treated with a cellophane band, the remainder with partial suture ligation.
Fifty-four dogs (21.3%) received peri-operative levetiracetam 20mg/kg orally every 8 hours for a minimum of 24 hours pre-operatively and a minimum of five days postoperatively. Dogs may have received levetiracetam for longer if prescribed by the referring veterinary surgeon.
Serum albumin was measured pre-operatively in 227 dogs (89.7%). The median albumin was 26.2g/l (range 7.9-35.8g/l), the reference range 49-71g/l.
Plasma ammonia was measured in 186 dogs (73.5%) pre-operatively. The median ammonia concentration was 163.0μmol/l (range 8-590), reference range 0-70μmol/l. Post-operative ammonia was measured in 119 dogs with a median of 82μmol/l (range 13-677). Paired pre and post-operative ammonia samples were available for 104 dogs (41.1%). There was a statistically significant decrease in ammonia after surgery from a median of 147.5μmol/l (range 8-544) to a median of 80.0μmol/l (range 13-677) (p<0.001).
Twelve dogs (4.74%) did not survive to discharge, seven of these dogs died or were euthanized for reasons not related to PANS. Three dogs died or were euthanized due to severe gastrointestinal haemorrhage, one dog due to suspected portal hypertension and pulmonary thromboembolism, one dog due to severe anaemia secondary to a coagulopathy, one dog due to a portal vein thrombus and one dog due to postoperative intussusception.
Twenty-eight dogs (11.1%) developed PANS (Table 5) (Table 4 ). Of the 28 dogs that suffered PANS, five (17.9%) did not survive to hospital discharge (Table 4 ). These dogs all suffered seizures meaning that 5/12 dogs (41.7%) that suffered seizures post-operatively died or were euthanized. None of the five dogs that died due to seizures received peri-operative levetiracetam, four out of the seven dogs that had seizures but survived to discharge did receive pre-operative leviteracetam.
Plasma osmolality was calculated at three time points. The median time interval from surgery to first sampling was 1 hour (range 0-4), from surgery to second sample was 8 hours (range [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] and from surgery to third sample was 24 hours (range [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] .
Osmolality was calculated at first sampling in 143 dogs with a median of 284.6 (269.6-316.0). Osmolality was calculated at second sampling in 131 dogs with a median of 282.7 
Univariable analysis
The results of the univariable binary logistic regression for possible risk factors of PANS and seizures are presented in Tables 5 and 6 .
Multivariable analysis
The Increasing age was significantly positively correlated with Osmolality 1 (p<0.001, R=0.349), Osmolality 2 (p<0.001, R=0.387), Osmolality 3 (p<0.001, R=0.563) and duration of clinical signs (p<0.001, R=0.401) and significantly negatively correlated with post-operative ammonia (p=0.005, R=0.255). Duration of clinical signs was significantly positively correlated with the duration of medical management (p<0.001, R=0.311).
Discussion
Although PANS do not occur frequently (11.1% in this study) they are a major cause of mortality in dogs that have undergone surgical CPSS attenuation. The unknown aetiology prevents aimed treatment and symptomatic treatment is centred on the use of anti-seizure medication to control neurological signs. Severe PANS may be refractory to such measures and this is reflected in a high mortality rate of 20-100%. 2, [5] [6] [7] 24, 32, 33 PANS may develop due to the triggering of a change in the CNS environment following anaesthesia and surgery that has been "set up" by the prior exposure of the astrocytes to one or more substances implicated in the pathogenesis of HE. 6, 9 To our knowledge there has not been identification of a risk factor that is predictive for PANS or seizure activity following surgical attenuation of a single CPSS. Our aim was to ascertain if clinical, biochemical or patient specific risk factors for PANS could be identified.
In this study the presence of HE immediately pre-operatively and age were independent risk factors for the development of PANS following surgical attenuation of a single CPSS. The odds of PANS occurring in dogs is increased 1.476 times with each year of age. The odds of PANS occurring in dogs with signs of HE immediately pre-surgery was 2.704 times that of those without.
Dogs that are older at the time of surgery have had longer exposure to alterations within the CNS. This fits with the suggestion that chronic and/or irreversible astrocyte damage by one or more neurotoxic substances is a trigger for the development of neurological abnormalities when the dog is challenged by an anaesthetic and surgical procedure. This is consistent with previous findings suggesting that older dogs are at an increased risk of post-operative complications, neurological or otherwise. 2, 6, 7, 9, 23, 34 A previous study suggested that age at diagnosis was not associated with long term survival and the authors concluded that there was no indication that surgical intervention should be performed early in life to be beneficial. 35 However, the results of the current study would suggest that delaying surgery could increase the risk of PANS.
Dogs that had signs of HE immediately prior to surgery either responded poorly to medical therapy or had not received medical therapy. CNS alterations may have been more severe, or the lack of medical therapy contributed to an unstable neurological state, resulting in a larger relative change in the CNS environment following shunt attenuation.
The findings of the current study support the notion that alterations in the CNS preoperatively are implicated in the neurological dysfunction seen post attenuation. This is in agreement with a previous study which indicated that dogs without pre-operative HE have fewer complications after CPSS attenuation, compared with dogs with pre-operative HE. 36 However, they are contrary to the results of another study which concluded that the presence of HE pre-operatively did not affect the likelihood of the development of PANS or seizure activity. 2 Other studies have not been able to draw any conclusions as to the significance of pre-operative HE in the development of PANS. 3, 9 The reasons for discrepancies between studies are likely to include sample size, the retrospective nature of the studies and the lack of clarification of timing of observation of HE. The improvement of HE with medical management makes this information critical. The separation of the clinical signs of pre-operative HE and post-operative PANS can be difficult, particularly in dogs that have undergone partial shunt attenuation. In this study, of the twenty eight dogs with PANS, nine dogs showed clinical signs of HE immediately pre-operatively. Paired (pre and post-operative) ammonia samples in three of the dogs affected by PANS showed a marked reduction in ammonia, lending evidence to two distinct neurological syndromes, and not simply a continuation of HE.
Hyperammonaemia is a common finding in dogs with HE, yet dogs that have undergone CPSS attenuation show a decrease in serum ammonia and this has been observed in dogs with PANS. 13, 24, 33 The conversion of ammonia to glutamine within the astrocyte is considered to be a factor in HE, resulting in osmotic stress and energy depletion. 16, 37 However the severity of neurological signs does not always correlate with hyperammonaemia and serum levels of ammonia can be normal in dogs, cats and humans with HE, suggesting other pathways are also involved. 13, 38, 39 Pre-operative ammonia levels were not associated with the development of PANS in this study, suggesting that the pathogenesis of PANS is complex and not related to a sole neurotoxin.
Interestingly, there were several risk factors evaluated in this study that were not found to be predictive of PANS. Peri-operative treatment with levetiracetam was instigated at our institution in 2012 as result of work by Fryer et al 3 suggesting peri-operative medication with levetiracetam reduced the risk of developing seizures post-operatively. However in the current study peri-operative levetiracetam did not affect the development of PANS or seizure activity which is therefore inconsistent with the aforementioned paper that only included dogs that developed seizures. Whilst prophylactic levetiracetam did not reduce PANS or seizures in this study, it did seem to be associated with reduced mortality in severely affected cases. However the cases receiving prophylactic levetiracetam were recent and therefore reduced mortality could be explained by increased experience treating PANS. It is also important to recognize that although cases receiving levetiracetam were treated for at least 24 hours pre-operatively and five days postoperatively, there may have been variation in the dose and duration of treatment. These differences highlight the need for a prospective, controlled study to interrogate the role of peri-operative anti-seizure medication for the prevention of PANS.
Neither extrahepatic or intrahepatic shunts were found to be at an increased risk of developing PANS or seizure activity in this study. Previously, one study found that dogs with extrahepatic shunts were significantly more likely to develop PANS and seizure activity compared to intrahepatic shunts. 2 Additionally, the degree of attenuation achieved was not predictive of neurological dysfunction in the current study.
In the univariable analysis age, the duration of the clinical signs, duration of medical management and osmolality at time points 2 and 3 were all significant, but of these, only age proved to be a risk factor in the multivariable model. The duration of clinical signs is closely related to age and these were significantly correlated. There was also a significant correlation between the duration of clinical signs and the duration of medical management, which is not surprising. The presence of HE pre-operatively was not significant in the univariable analysis but was a risk factor for PANS in the final model. There were also significant correlations between osmolality and age. Osmolality, specifically sodium, has been implicated in the pathogenesis of HE in human medicine 16, 29, 40 and imbalance is likely to be implicated in HE in dogs, contributing to the alzheimer type II changes seen with astrocyte swelling. Interestingly, central pontine myelinolysis is associated with rapid correction of hyponatraemia, 28 and therefore increased osmolality. In the current study osmolality was greater in dogs affected by PANS and seizures. The significant differences in osmolality between dogs with and without PANS is an interesting finding and worthy of further study. It is possible that the changes in post-operative osmolality are directly related to the occurrence of PANS, it is also possible that they are result of PANS. Additionally, it is possible that osmolality is related to age.
The retrospective nature of this study is limiting, with smaller sub groups for several important variables, particularly osmolality. Although analysis of complications and behavioural changes used a detailed grading scale, retrospective analysis of these records is open to interpretation. Furthermore, information has been collected over an extended period. While this allows a large dataset to be analysed it also introduces variability in the surgical, anaesthetic and medical management.
Age and the presence of HE immediately pre-operatively were identified as risk factors for PANS and seizures in this study, suggesting surgery should not be delayed for a prolonged period and emphasizing the need to stabilise clinical signs of HE before surgery. Further work is necessary to elucidate the underlying mechanism of PANS so that strategies can be targeted to prevent or more effectively treat PANS. Although it will be difficult to enroll sufficient dogs in a timely manner, a randomised, prospective study would be invaluable to confirm if there is any potential benefit of prophylactic antiseizure medications in dogs undergoing surgery for a CPSS. 
